<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204694</url>
  </required_header>
  <id_info>
    <org_study_id>7350</org_study_id>
    <nct_id>NCT04204694</nct_id>
  </id_info>
  <brief_title>Study of the Role of Interferon αon the Endothelial Dysfunction During Septic Shock</brief_title>
  <acronym>INTERSEP</acronym>
  <official_title>Study of the Role of Interferon αon the Endothelial Dysfunction During Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is the most severe form of a bacterial infection, affecting 24 million patients
      per year worldwide, with a high mortality (&gt; 30%).

      Septic shock is defined by an acute circulatory failure, with low blood pressure and
      insufficient oxygen supply to organs. This circulatory failure is related to vascular
      damages, in which the endothelial vascular tissue is impaired by inflammatory mechanisms,
      with release of circulating endothelial cells in the blood.

      Therefore, modulating inflammation on the vascular endothelial tissue could be a therapeutic
      strategy, and the investigators focus on the role of the type I interferons on the
      endothelial tissue because of the demonstrated role of type I interferons during septic
      shock.

      Thus the investigators proceed to an observational study, in which the primary purpose will
      be to show a higher expression of type I interferon receptors on circulating endothelial
      cells in patients with septic shock compared to control subjects.

      Concerning secondary purposes, the investigators will record mortality at d3, d7 and d28,
      perform assays about types I, II and III interferons in plasma, and test anti-interferon on
      endothelial cells ex vivo
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of the activated interferon-α receptors (IFNAR) by circulant endothelial cells</measure>
    <time_frame>Within 12 hours following the onset of norepinephrin for septic shock (day 1)</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Patient in septic shock</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>blood donor tests</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3-time blood sampling for septic shock patients</intervention_name>
    <description>15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock</description>
    <arm_group_label>Patient in septic shock</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Only one blood sampling for controls patients</intervention_name>
    <description>15 mL blood are sampled from a blood donation</description>
    <arm_group_label>blood donor tests</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will have two groups :

          1. Patients with septic shock hospitalized in the ICU from Strasbourg University Hospital

          2. Controls: blood donors recruited by the French blood establishment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  For all subjects

          -  Age &gt; 18 years old

          -  For females: negative pregnancy test

          -  Subject covered by health insurance

          -  Written consent

          -  Patients with septic shock

          -  Patients must be in ICU

          -  Septic shock defined by the Sepsis-3 criteria [1]

          -  Inclusion within the 12 hours following the onset of norepinephrin

          -  Controls :

          -  Blood donors

        Exclusion criteria:

          -  Moribund

          -  Age &lt; 18 years old

          -  Absence of written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raphaël CLERE-JEHL</last_name>
    <phone>33 3 69 55 13 48</phone>
    <email>raphael.clere@chru-strasbourg.fr</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

